Markets:

Overview

News

Currencies

International

Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

8.790 +0.430 (+5.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Earnings Preview For Fulcrum Therapeutics ↗

March 02, 2022

Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment ↗

December 06, 2021

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for...

Via Benzinga

Analyzing Fulcrum Therapeutics's Unusual Options Activity ↗

August 12, 2021

On Thursday, shares of Fulcrum Therapeutics (NASDAQ:FULC)...

Via Benzinga

Why Are Fulcrum Therapeutics Shares Trading Higher Today? ↗

August 11, 2021

Fulcrum Therapeutics Inc (NASDAQ:FULC) is trading higher a...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 06, 2021

Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market value of their outstanding shares is at $431.7...

Via Benzinga

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Fulcrum Therapeutics's Return On Capital Employed Overview ↗

September 22, 2021

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 sales of $4.38 million. Earnings fell to a loss of $19.68 million, resulting in a 15.48% decrease from last...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

Cramer Weighs In On Lennar, Alibaba And More ↗

September 15, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he needs something less speculative than Original BARK Co (NYSE: BARK). He suggested Zoetis Inc (NYSE: ZTS),...

Via Benzinga

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab ↗

September 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...

Via Benzinga

The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO ↗

August 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗

September 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

August 17, 2021

Citigroup cut the price target on Wix.com Ltd. (NYSE:WIX...

Via Benzinga

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among...

Via Talk Markets

Topics Initial Public Offering

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration ↗

August 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Topics Intellectual Property

The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-...

Via Benzinga

Topics Initial Public Offering

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal ↗

August 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (...

Via Benzinga

Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher ↗

August 12, 2021

Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also rose, gaining 0.19% to 4,456.37. The U.S. has...

Via Benzinga

Topics Stocks

Why Fulcrum Therapeutics Popped Again on Tuesday ↗

August 11, 2021

Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.

Via The Motley Fool

Stocks That Hit 52-Week Highs On Monday ↗

August 23, 2021

Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs. Noteables: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG...

Via Benzinga

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 12, 2021

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic...

Via Benzinga

Topics Initial Public Offering

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021 ↗

August 11, 2021

Upgrades According to Barclays, the prior rating for Albertsons Companies Inc (NYSE:

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 11, 2021

Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The...

Via Benzinga

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 10, 2021

Gainers CohBar (NASDAQ:CWBR) shares incr...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.